Provided by Tiger Trade Technology Pte. Ltd.

Pliant Therapeutics, Inc.

1.17
-0.0600-4.88%
Post-market: 1.16-0.0085-0.73%18:36 EDT
Volume:726.68K
Turnover:863.64K
Market Cap:72.44M
PE:-0.48
High:1.26
Open:1.24
Low:1.15
Close:1.23
52wk High:1.95
52wk Low:1.09
Shares:61.91M
Float Shares:55.57M
Volume Ratio:1.79
T/O Rate:1.31%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.4336
EPS(LYR):-2.4336
ROE:-61.55%
ROA:-30.15%
PB:0.40
PE(LYR):-0.48

Loading ...

BRIEF-Pliant Therapeutics Announces Upcoming Presentation Of Phase 1 Clinical Trial Of PLN-101095 In Patients With Solid Tumors At The 2026 Aacr Annual Meeting

Reuters
·
Mar 18

Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of Pln-101095 in Patients With Solid Tumors at the 2026 Aacr Annual Meeting

THOMSON REUTERS
·
Mar 18

Pliant Therapeutics Is Maintained at Hold by Canaccord Genuity

Dow Jones
·
Mar 14

How Shareholder Activism Could Disrupt Pliant Therapeutics’ Strategy, Costs, and Stock Performance

TIPRANKS
·
Mar 13

Oppenheimer Remains a Hold on Pliant Therapeutics (PLRX)

TIPRANKS
·
Mar 13

Pliant Therapeutics Q4 net loss narrows 53% to USD 23.6 million

Reuters
·
Mar 12

BRIEF-Pliant Therapeutics Q4 Net Income USD -23.577 Million

Reuters
·
Mar 12

Pliant Therapeutics Q4 Operating Expenses USD -23.577 Million

THOMSON REUTERS
·
Mar 12

Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2025 Financial Results

THOMSON REUTERS
·
Mar 12

Pliant Therapeutics Extends Stockholder Rights Agreement Expiration

TIPRANKS
·
Mar 04

Pliant Therapeutics Inc expected to post a loss of 40 cents a share - Earnings Preview

Reuters
·
Feb 28

Tarsus Pharmaceuticals Names Former Allergan CEO David Pyott to Board

Reuters
·
Feb 18

Pliant Therapeutics Unveils Data on Oral Integrin Inhibitor for ICI-Resistant Tumors

Reuters
·
Jan 27

Pliant Therapeutics Files Initial Beneficial Ownership Statement for Chief Operating Officer Minnie Kuo

Reuters
·
Dec 23, 2025

Pliant Therapeutics Appoints Minnie Kuo as Chief Operating Officer

Reuters
·
Dec 17, 2025

Pliant Therapeutics Inc - Terminates Cmo ÉRic Lefebvre Effective December 15 - SEC Filing

THOMSON REUTERS
·
Dec 09, 2025

Pliant Therapeutics Announces Departure of Chief Medical Officer Éric Lefebvre

Reuters
·
Dec 09, 2025

Pliant Cancer Drug Boosts Responses When Paired With Merck's Blockbuster Keytruda In Tough-To-Treat Tumors

Benzinga_recent_news
·
Dec 05, 2025

BRIEF-Pliant Therapeutics Announces Interim Data From PLN-101095

Reuters
·
Dec 04, 2025

Pliant Therapeutics Announces Interim Data From Pln-101095 in Patients With Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors

THOMSON REUTERS
·
Dec 04, 2025